Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Based on a potential role for serotonin receptors in fibromyalgia, we investigated the efficacy and tolerability of treatment with tropisetron, a highly selective, competitive inhibitor of the 5-HT3 receptor. METHODS: In this prospective, multicenter, double-blind, parallel-group, dose-finding study, 418 patients suffering from primary fibromyalgia (ACR criteria) were randomly assigned to receive either placebo, 5 mg, 10 mg or 15 mg tropisetron once daily, respectively. The duration of treatment was 10 days. The clinical response was measured by changes in pain-score, visual analog scale (VAS), and the number of painful tender-points. RESULTS: Treatment with 5 mg tropisetron resulted in a significantly higher response rate (39.2%) when compared with placebo (26.2%) (p=0.033). The absolute reduction in pain-score was -13.5% for 5 mg tropisetron, -13.0% for 10 mg tropisetron, and -6.3% for placebo (p<0.05). The effects of 15 mg tropisetron were similar to placebo, thus suggesting a bell-shaped dose-response curve. Compared with placebo, treatment with 5 mg tropisetron led to a significant improvement (p<0.05) in VAS, while a clear trend in terms of clinical benefit was seen with 10 mg tropisetron. The number of painful tender-points was also reduced significantly (p=0.002) in the 5 mg tropisetron group. Of interest, during the 12-month follow-up period, pain intensity of responders on 5 mg and 10 mg tropisetron was still markedly below baseline. The treatment was well tolerated, with gastro-intestinal complaints being the most frequently reported side effects, in keeping with the known safety profile for 5-HT3 receptor antagonists. CONCLUSIONS: This study demonstrates the efficacy of short-term treatment with 5 mg tropisetron once daily in primary fibromyalgia. Treatment was well tolerated and prolonged clinical benefits were seen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752
Biology and therapy of fibromyalgia. New therapies in fibromyalgia.
Arnold (2006) · Arthritis Research & Therapy · doi:10.1186/ar1971 · Cited by 145
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-7020-4086-3.00033-3 · Cited by 86
Novel pharmacotherapy for fibromyalgia
Wood, P. B., Holman, A. J., & Jones, K. D. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.829 · Cited by 30
Metadata
- Authors
- Färber, T. S.
- Venue
- Scandinavian Journal of Rheumatology
- Publisher
- Informa UK Limited
- Published
- 2000-01
- Volume
- 29
- Issue
- sup113
- Pages
- 49-54
- ISSN
- 0300-9742 (ISSN-L)
- 1502-7732
- OpenAlex
- W2171487934
- Cited by
- 98
- References
- 0
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist. https://app.cochat.ai/papers/10.1080/030097400446643
- The paper
- Färber, T. S. (2000). Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist. Scandinavian Journal of Rheumatology. https://doi.org/10.1080/030097400446643
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.